Cargando…
Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders
INTRODUCTION: Infectious and immunological theories of schizophrenia have been discussed for over a century. Contradictory results for infectious agents in association with schizophrenia spectrum disorders (SSDs) were reported. The rationale of this study was to investigate intrathecal antibody synt...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338642/ https://www.ncbi.nlm.nih.gov/pubmed/35906648 http://dx.doi.org/10.1186/s12987-022-00355-7 |
_version_ | 1784760015437955072 |
---|---|
author | Runge, Kimon Balla, Agnes Fiebich, Bernd L. Maier, Simon J. Pankratz, Benjamin Schlump, Andrea Nickel, Kathrin Dersch, Rick Domschke, Katharina Tebartz van Elst, Ludger Endres, Dominique |
author_facet | Runge, Kimon Balla, Agnes Fiebich, Bernd L. Maier, Simon J. Pankratz, Benjamin Schlump, Andrea Nickel, Kathrin Dersch, Rick Domschke, Katharina Tebartz van Elst, Ludger Endres, Dominique |
author_sort | Runge, Kimon |
collection | PubMed |
description | INTRODUCTION: Infectious and immunological theories of schizophrenia have been discussed for over a century. Contradictory results for infectious agents in association with schizophrenia spectrum disorders (SSDs) were reported. The rationale of this study was to investigate intrathecal antibody synthesis of the most frequently discussed neurotropic pathogens using a pathogen-specific antibody index (AI) in patients with SSD in comparison to controls. METHODS: In 100 patients with SSD and 39 mentally healthy controls with idiopathic intracranial hypertension (IIH), antibodies against the herpesviruses EBV, CMV, and HSV 1/2 as well as the protozoan Toxoplasma gondii, were measured in paired cerebrospinal fluid (CSF) and serum samples with ELISA-kits. From these antibody concentrations the pathogen-specific AIs were determined with the assumption of intrathecal antibody synthesis at values > 1.5. RESULTS: No significant difference was detected in the number of SSD patients with elevated pathogen-specific AI compared to the control group. In a subgroup analysis, a significantly higher EBV AI was observed in the group of patients with chronic SSD compared to patients with first-time SSD diagnosis (p = 0.003). In addition, two identified outlier EBV patients showed evidence for polyspecific immune reactions (with more than one increased AI). CONCLUSIONS: Evidence for the role of intrathecal EBV antibody synthesis was found in patients with chronic SSD compared to those first diagnosed. Apart from a possible infectious factor in SSD pathophysiology, the evidence for polyspecific immune response in outlier patients may also suggest the involvement of further immunological processes in a small subgroup of SSD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12987-022-00355-7. |
format | Online Article Text |
id | pubmed-9338642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93386422022-07-31 Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders Runge, Kimon Balla, Agnes Fiebich, Bernd L. Maier, Simon J. Pankratz, Benjamin Schlump, Andrea Nickel, Kathrin Dersch, Rick Domschke, Katharina Tebartz van Elst, Ludger Endres, Dominique Fluids Barriers CNS Research INTRODUCTION: Infectious and immunological theories of schizophrenia have been discussed for over a century. Contradictory results for infectious agents in association with schizophrenia spectrum disorders (SSDs) were reported. The rationale of this study was to investigate intrathecal antibody synthesis of the most frequently discussed neurotropic pathogens using a pathogen-specific antibody index (AI) in patients with SSD in comparison to controls. METHODS: In 100 patients with SSD and 39 mentally healthy controls with idiopathic intracranial hypertension (IIH), antibodies against the herpesviruses EBV, CMV, and HSV 1/2 as well as the protozoan Toxoplasma gondii, were measured in paired cerebrospinal fluid (CSF) and serum samples with ELISA-kits. From these antibody concentrations the pathogen-specific AIs were determined with the assumption of intrathecal antibody synthesis at values > 1.5. RESULTS: No significant difference was detected in the number of SSD patients with elevated pathogen-specific AI compared to the control group. In a subgroup analysis, a significantly higher EBV AI was observed in the group of patients with chronic SSD compared to patients with first-time SSD diagnosis (p = 0.003). In addition, two identified outlier EBV patients showed evidence for polyspecific immune reactions (with more than one increased AI). CONCLUSIONS: Evidence for the role of intrathecal EBV antibody synthesis was found in patients with chronic SSD compared to those first diagnosed. Apart from a possible infectious factor in SSD pathophysiology, the evidence for polyspecific immune response in outlier patients may also suggest the involvement of further immunological processes in a small subgroup of SSD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12987-022-00355-7. BioMed Central 2022-07-29 /pmc/articles/PMC9338642/ /pubmed/35906648 http://dx.doi.org/10.1186/s12987-022-00355-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Runge, Kimon Balla, Agnes Fiebich, Bernd L. Maier, Simon J. Pankratz, Benjamin Schlump, Andrea Nickel, Kathrin Dersch, Rick Domschke, Katharina Tebartz van Elst, Ludger Endres, Dominique Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title | Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title_full | Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title_fullStr | Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title_full_unstemmed | Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title_short | Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
title_sort | antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338642/ https://www.ncbi.nlm.nih.gov/pubmed/35906648 http://dx.doi.org/10.1186/s12987-022-00355-7 |
work_keys_str_mv | AT rungekimon antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT ballaagnes antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT fiebichberndl antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT maiersimonj antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT pankratzbenjamin antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT schlumpandrea antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT nickelkathrin antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT derschrick antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT domschkekatharina antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT tebartzvanelstludger antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders AT endresdominique antibodyindicesofinfectiouspathogensfromserumandcerebrospinalfluidinpatientswithschizophreniaspectrumdisorders |